Investor's Business Daily on MSN
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss
Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The ...
The FDA clearance of the Zeto New Wave™ marks Zeto's third FDA-cleared device, alongside Zeto WR19 and Zeto ONE. Zeto offers ...
Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results